What question did this study set out to answer?

The research aims to validate existing clinical models for predicting pathological complete response (pCR) in rectal cancer patients undergoing neoadjuvant therapy.

July 26, 2026CancersOpen Access

Predicting Pathological Complete Response in Rectal Cancer: External Validation of Clinical Models

View Full Paper

Ask AI

Bookmark

Authors

JCJesús Pedro Paredes Cotoré FLFernando Fernández López

Discussion

Member takes

Overview

Randomized trial validates clinical models predicting pathological complete response in rectal cancer, indicating limited application.

Key Points

The research aims to validate existing clinical models for predicting pathological complete response (pCR) in rectal cancer patients undergoing neoadjuvant therapy.
Single-centre cohort study of rectal cancer patients treated with neoadjuvant therapy from 2016 to 2025
Assessment of two published clinical models for pCR using their original coefficients and local refitting
Decision-curve analysis to evaluate clinical utility and development of a local six-predictor model.
Of 425 patients, 85 achieved pCR (20.0%) with variation by regimen: 27.9% for total neoadjuvant therapy, 22.8% for chemoradiotherapy, and 10.3% for short-course radiotherapy.
The Wang model had a modest c-statistic of 0.62, with a slope of 0.57 for predictor effects; Tan's model performed worse (c-statistic 0.58).
Local refitting of the best model did not improve its predictive power, indicating limitations in the original predictors.

Cite This Study

Cotoré et al. (2026) studied this question.

synapsesocial.com/papers/6a65a84ed3aea3239cd78cdf https://doi.org/10.3390/cancers18152390

View Full Paper

Ask AI

Bookmark

July 26, 2026CancersOpen Access

Predicting Pathological Complete Response in Rectal Cancer: External Validation of Clinical Models

View Full Paper

Ask AI

Bookmark

Authors

JCJesús Pedro Paredes Cotoré FLFernando Fernández López

Discussion

Member takes

Overview

Randomized trial validates clinical models predicting pathological complete response in rectal cancer, indicating limited application.

Key Points

The research aims to validate existing clinical models for predicting pathological complete response (pCR) in rectal cancer patients undergoing neoadjuvant therapy.
Single-centre cohort study of rectal cancer patients treated with neoadjuvant therapy from 2016 to 2025
Assessment of two published clinical models for pCR using their original coefficients and local refitting
Decision-curve analysis to evaluate clinical utility and development of a local six-predictor model.
Of 425 patients, 85 achieved pCR (20.0%) with variation by regimen: 27.9% for total neoadjuvant therapy, 22.8% for chemoradiotherapy, and 10.3% for short-course radiotherapy.
The Wang model had a modest c-statistic of 0.62, with a slope of 0.57 for predictor effects; Tan's model performed worse (c-statistic 0.58).
Local refitting of the best model did not improve its predictive power, indicating limitations in the original predictors.

Cite This Study

Cotoré et al. (2026) studied this question.

synapsesocial.com/papers/6a65a84ed3aea3239cd78cdf https://doi.org/10.3390/cancers18152390

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark